The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

Environmental Health Perspectives, a journal funded by the National Institutes of Health (NIH), announced that it would pause new submissions.

Florida state lawmakers have approved a bill to ban the addition of fluoride to public drinking water, a move that public health experts say could harm dental health across the state.

The Food and Drug Administration (FDA) has cleared the Jewel ® Patch Wearable Cardioverter Defibrillator (Patch-WCD) for adult patients aged 18 years and older who are at risk for sudden cardiac ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Measles may reestablish endemicity, with an estimated 851,300 cases over 25 years at current vaccination rates.

Elamipretide, a cell-permeable peptide compound, is designed to improve mitochondrial function by targeting the inner mitochondrial membrane where it binds reversibly to cardiolipin.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Children receiving multiple antibiotic courses between birth and age 2 years may have a higher risk for some chronic conditions.

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.